Virus News and Research

Latest Virus News and Research

$Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010$

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.

8 Jun 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

7 Jun 2010

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.

7 Jun 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Researchers discover svRNA component that may help develop universal anti-viral treatment

Researchers at Mount Sinai School of Medicine have discovered a novel component of the influenza virus that may be the key to disabling the virus's ability to replicate itself and to developing a universal anti-viral treatment. The findings were published June 1 online in Proceedings of the National Academy of Sciences.

4 Jun 2010

WHO says H1N1 remains pandemic

WHO Director-General Margaret Chan on Thursday announced the WHO still considers H1N1 (swine) flu a pandemic, despite the fact "its most intense activity has passed in many parts of the world," Reuters reports (Lynn, 6/3).

4 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.

3 Jun 2010

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

The National Institutes of Health has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world.

3 Jun 2010

Universal testing for HIV can do more harm than good

The idea of early detection and cure is appealing. But if the test is unreliable, and the treatment itself harmful, universal testing can do more harm than good.

3 Jun 2010

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

According to the Canadian Flu Report released today, 40 per cent of parents are now more interested in vaccinating themselves and their children against seasonal flu following last year's H1N1 outbreak. Yet, significant barriers and misinformation are still preventing many from actually seeking proper flu protection for their families.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.

2 Jun 2010

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by Alnylam scientists and collaborators from Mount Sinai School of Medicine. In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced small non-coding RNAs, called small viral RNAs (svRNAs), which play a critical role in the replication of influenza A virus.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Only about one in three young women has received the human papillomavirus vaccine to help prevent cervical cancer, according to a new report from researchers at Washington University School of Medicine in St. Louis.

2 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

Virus News and Research

Latest Virus News and Research

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Researchers discover svRNA component that may help develop universal anti-viral treatment

WHO says H1N1 remains pandemic

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

Case report on clear cell ICC

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

Universal testing for HIV can do more harm than good

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

Research findings advance the effort to develop AIDS vaccine

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

New technique transforms iPS cells into natural tumor killers

A new way of characterising biomolecules eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in